ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1253

Gray Intensity Ratio Indices as a Method of Discrimination Between Changes Induced by Sport and by Spondyloarthritis in Load-bearing Entheses
Abstract Number: 1254

Ultra High‐Frequency Ultrasound of Labial Salivary Glands in Primary Sjögren’s Syndrome: A Promising Tool to Identify Lymphoproliferative Lesions in Unusual Sites
Abstract Number: 1255

Rheumatologists Overcall Sacroiliitis on X-ray and MRI in Axial Spondyloarthritis Patients: Data from the BelGian Inflammatory Arthritis and SpoNdylitis cohorT (Be-GIANT)
Abstract Number: 1256

A Machine Learning Pipeline for Prediction of Bone Marrow Oedema Along the Sacroiliac Joints on Magnetic Resonance Imaging
Abstract Number: 1257

Assessing the Effectiveness of Tocilizumab in Giant Cell Arteritis by PET: Multicenter Study of 101 Patients of Clinical Practice
Abstract Number: 1258

Development of International Consensus on a Standardized Image Acquisition Protocol for Diagnostic Evaluation of the Sacroiliac Joints by MRI – an ASAS-SPARTAN Collaboration
Abstract Number: 1259

Characteristics of Sacroiliac Joint in Patient with Skin Psoriasis, Without Rheumatological Manifestations: A Controlled Study Using CT Scan
Abstract Number: 1260

Tenderness and Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis
Abstract Number: 1261

Scoring Structural Damage in Rheumatoid Arthritis by Ultrasound: Results from a Delphi Process and Web-Based Reliability Exercise by the OMERACT Ultrasound Working Group
Abstract Number: 1262

Clinical and Ultrasound-based Composite Disease Activity Indices and Radiographic Progression in Rheumatoid Arthritis
Abstract Number: 1263

Impact of Cardiovascular Risk on the Diagnostic Accuracy of the Ultrasound Halo Score for Giant Cell Arteritis
Abstract Number: 1264

Does Vein Wall Thickness Have Prognostic Value in Behcet’s Disease? A Prospective Follow up Study
Abstract Number: 1265

External Validation of a Giant Cell Arteritis Probability Score (GCAPS) to Risk Stratify GCA Referrals: Experience from a United Kingdom Fast Track Clinic
Abstract Number: 1266

Time-course Ultrasonography to Predict Flare After Discontinuation of Biologics in Patients with Rheumatoid Arthritis Achieving Stringent Remission
Abstract Number: 1267

Accuracy of Financial Disclosures in American-Based Rheumatology Journals

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].